Lung cancer screening program for patients with COPD or emphysema
Official title: Registry of Patients Included in the DEPRECAP (Lung Cancer Screening Porgramme by Low-dose Computed Tomography for Patients With Chronic Obstructive Pulmonary Disease (COPD) or Emphysema.
Run by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · NCT06690385 · Data updated 2026-11-12
This study is testing if regular lung cancer screenings can help people with COPD or emphysema catch lung cancer earlier and live longer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 55 Years to 75 Years |
| Sex | All |
| Enrollment | 1998 (estimated) |
| Sponsor | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Academic / other |
| Locations | 2 sites (Madrid and 1 other locations) |
| Status | Recruiting |
| Started | January 14, 2014 |
| Main results expected | November 13, 2024 |
| Study ends | November 13, 2024 |
| Registry record updated | November 15, 2024 |
| Trial ID | NCT06690385 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are current or former smokers aged 55-75 with a history of significant smoking exposure and a diagnosis of COPD or emphysema.
✕Probably not a fit
Patients with a recent history of cancer or other serious medical conditions that pose a significant risk of death may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The DEPRECAP study is an ongoing observational program aimed at screening for lung cancer in individuals with COPD or emphysema. It recruits participants from pulmonary clinics in Madrid, Spain, and involves annual low-dose computed tomography (LDCT) and pulmonary function tests until participants reach age 75 or have 15 years of smoking abstinence. The study seeks to gather scientific evidence on the benefits of lung cancer screening in this high-risk population and aims to reduce mortality rates associated with late-stage lung cancer diagnosis. Additionally, it will create a registry of clinical, radiological, functional data, and biological samples for future research.
Why it matters
Potential benefit: If successful, this program could significantly reduce lung cancer mortality rates in patients with COPD or emphysema through early detection.
How similar studies have gone: Other studies have shown success with similar lung cancer screening approaches in high-risk populations, indicating potential for positive outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Current or former smokers (\>15 years of abstinence) with a cumulative smoking exposure of \> 30 pack-years * Diagnosis of COPD according to the GOLD guidelines and/or emphysema identified by LDCT and/or a carbon monoxide diffusing capacity (DLCO) lower than 80% of predicted (as per the Global Lung Function Initiative (GLI) equations) Exclusion Criteria: * Individuals with a recent history of cancer (except non-melanoma skin cancer or carcinoma in situ) as well as those with other medical conditions that posed a significant risk of death were excluded from the study.
Where it's running
-
Fundación Jimenez Díaz Universitary Hospital
Madrid, Spain Recruiting -
Pneumology department. Fundación Jimenez Díaz University Hospital
Madrid, Spain Recruiting
Study contacts
- Principal investigator: Carolina Gotera, MD — Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Study coordinator: Carolina Gotera, MD
- Email: carolina.gotera@fjd.es
- Phone: +34 915504800
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using breath analysis to identify multiple lung diseases
This study is testing if analyzing breath samples can help identify different lung diseases like lung cancer and COPD in a large group of 10,000 people.
-
Biomarker clues for COPD, IPF, and lung cancer
This study tests whether inflammation, immune, genetic, and epigenetic markers at enrollment can explain how COPD, IPF, or lung cancer present and behave, in order to see if these markers can predict outcomes over a year.
-
Implant to help adults with severe emphysema
This study will test whether an implantable artificial bronchus can improve breathing and safety in adults with severe COPD/emphysema.
-
Implantable Artificial Bronchus 50 Flex for adults with severe emphysema
This tests a small implant called the IAB 50 Flex to see if it is safe and helps adults with severe COPD or emphysema breathe and move more easily.
-
Multidisciplinary sarcopenia clinic to diagnose and treat muscle loss from COPD
This project will try a multidisciplinary sarcopenia clinic to see if it improves muscle mass, function, and overall health for COPD patients with CT-confirmed muscle loss after a hospitalization.
-
Bronchoscopic release of trapped air in hyperinflated emphysematous lungs
This trial tests if placing permanent Apreo BREATHE airway scaffold implants by bronchoscopy, together with usual medical care, helps adults with COPD and emphysema who remain short of breath from lung hyperinflation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.